A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer

[1] Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J Clin 71 209-249

[2] Ferlay J(2022)Current and future burden of breast cancer: Global statistics for 2020 and 2040 Breast 66 15-23

[3] Siegel RL(2023)Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer CA Cancer J Clin 73 480-515

[4] Laversanne M(2022)Breast Cancer Statistics, 2022 CA Cancer J Clin 72 524-541

[5] Soerjomataram I(2021)Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status Sci Rep 11 2259-201

[6] Jemal A(2023)Survival outcomes in patients with hormone receptor-positive metastatic breast cancer with low or no ERBB2 expression treated with targeted therapies plus endocrine therapy JAMA Netw Open 6 189-1369

[7] Arnold M(2021)Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer Breast Cancer Res Treat 190 1661-861

[8] Morgan E(2019)Should all patients with HR-positive HER2-negative metastatic breast cancer receive CDK 4/6 inhibitor as first-line based therapy? A network meta-analysis of data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT trials Cancers (Basel) 11 816-624

[9] Rumgay H(2020)Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis Curr Probl Cancer 44 805-784

[10] Mafra A(2023)Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 - metastatic or advanced breast cancer patients: a network meta-analysis BMC Cancer 23 1360-455

[1] Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J Clin 71 209-249

[2] Ferlay J(2022)Current and future burden of breast cancer: Global statistics for 2020 and 2040 Breast 66 15-23

[3] Siegel RL(2023)Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer CA Cancer J Clin 73 480-515

[4] Laversanne M(2022)Breast Cancer Statistics, 2022 CA Cancer J Clin 72 524-541

[5] Soerjomataram I(2021)Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status Sci Rep 11 2259-201

[6] Jemal A(2023)Survival outcomes in patients with hormone receptor-positive metastatic breast cancer with low or no ERBB2 expression treated with targeted therapies plus endocrine therapy JAMA Netw Open 6 189-1369

[7] Arnold M(2021)Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer Breast Cancer Res Treat 190 1661-861

[8] Morgan E(2019)Should all patients with HR-positive HER2-negative metastatic breast cancer receive CDK 4/6 inhibitor as first-line based therapy? A network meta-analysis of data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT trials Cancers (Basel) 11 816-624

[9] Rumgay H(2020)Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis Curr Probl Cancer 44 805-784

[10] Mafra A(2023)Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 - metastatic or advanced breast cancer patients: a network meta-analysis BMC Cancer 23 1360-455